Plesner advises Gubra in connection with its proposed IPO
Gubra A/S (Gubra), a company specialised in pre-clinical services within metabolic and fibrotic diseases and with a strong pipeline of novel discovery projects, has today published a prospectus and offer price for its initial public offering (IPO) and subsequent admission to trading and official listing of its shares on Nasdaq Copenhagen A/S.
The first day of trading of the temporary purchase certificates representing the new shares is expected to be 30 March 2023.
Plesner and its ECM team is proud to have worked together with Gubra on reaching this milestone.
Gubra, founded in 2008 in Denmark, is specialised in high-end pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.
Gubra's activities are focused on the early stages of the drug development value chain and are organised in two business areas - contract research organisation services and discovery & partnerships - benefitting from cross-segment synergies. Together, the two business areas create an entity capable of generating a steady cash flow from the contract research organisation segment, while at the same time enjoying a biotechnology upside in the form of potential development milestone payments and potential royalties in the discovery & partnerships segment.